Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions

This study reveals that branched actin-driven membrane protrusions (BAMPs) function not merely as downstream outputs but as active positive feedback regulators of oncogenic KRAS signaling, where they enhance KRAS-TIAM1 interactions to inactivate the merlin tumor suppressor and drive proliferation independently of the MAPK pathway.

The Gist

The Big Idea: The "Shape" of a Cancer Cell is Part of the Engine

For decades, scientists have known that a specific gene mutation called KRAS is a major driver of deadly cancers (like pancreatic and lung cancer). We also knew that cells with this mutation look weird—they grow long, wavy "fingers" or "ruffles" on their surface.

For a long time, scientists thought these weird shapes were just a side effect. They thought: "The KRAS mutation is the engine, and the weird shape is just the exhaust fumes."

This paper flips that idea on its head. The researchers discovered that the weird shape isn't just exhaust; it's actually part of the engine itself. The shape helps the cancer grow faster. If you stop the cell from making those "fingers," the cancer slows down, even if the KRAS mutation is still there.

---

The Analogy: The "Crowded Party" vs. The "VIP Lounge"

Imagine the inside of a cell is a giant, open-plan office building.

1. The Bad Guys (Oncogenic KRAS): These are the troublemakers trying to start a riot (uncontrolled cell division).
2. The Enforcers (TIAM1 & RAC1): These are the muscle the troublemakers need to get things done.
3. The Security Guard (Merlin): This is the tumor suppressor. Its job is to stop the riot and keep the peace.

The Old Theory

Previously, scientists thought the KRAS troublemakers just shouted orders across the whole office. The security guard (Merlin) could hear them and try to stop them.

The New Discovery: The "VIP Lounge" (BAMPs)

The researchers found that the KRAS troublemakers build a special, tiny, crowded room on the edge of the cell called a BAMP (Branched Actin-driven Membrane Protrusion). Think of this as a VIP Lounge or a soundproof booth.

• Crowding Effect: In this tiny, crowded booth, the KRAS troublemakers and their muscle (TIAM1) are forced to stand right next to each other. They can't ignore each other. This makes their "riot planning" (signaling) happen 4 times faster than in the open office.
• The Security Guard's Dilemma: The security guard (Merlin) usually patrols the whole office. But because the troublemakers are hiding in this tiny, crowded booth, the security guard gets trapped inside the booth with them. Once trapped, the troublemakers knock the security guard unconscious (inactivate him).
• The Result: With the security guard knocked out, the riot (cell division) goes wild. The cell starts multiplying rapidly, producing a protein called Cyclin D1 that tells the cell to divide.

The Surprising Twist: Bypassing the "Main Highway"

Usually, when KRAS causes cancer, it uses a famous highway called the MAPK pathway to send its messages. Doctors have spent years building roadblocks (drugs) to stop traffic on this highway.

Here is the shocker: The researchers found that these "VIP Lounges" (BAMPs) allow the cancer to bypass the highway entirely.

• Even if you block the main MAPK highway with drugs, the cancer can still grow because it has this secret backdoor (the BAMPs) that keeps the riot going.
• This explains why some cancer drugs stop working: the cancer cells just switch to using their "VIP Lounge" to keep growing.

How They Proved It (The "What If" Experiments)

The team used some high-tech tools to test this theory:

1. The "Stop Button": They used a drug (CK-666) to stop the cell from building those "fingers" (BAMPs).
   • Result: The VIP Lounge disappeared. The troublemakers were scattered in the open office. The security guard (Merlin) woke up and stopped the riot. The cancer cells stopped growing, even though the KRAS mutation was still there.
2. The "Fake VIP Lounge": They forced normal cells to build these fingers artificially.
   • Result: The cells started growing uncontrollably, proving that the shape itself drives the cancer.
3. The "Real World" Check: They looked at actual tumors in mice. They saw that the cells on the outside edge of the tumor (where they have room to grow fingers) were the ones growing the fastest. The cells in the center (where they are squished and can't make fingers) were slower.

Why This Matters for Patients

This discovery changes how we might treat cancer in the future:

• New Targets: We can't just target the KRAS gene anymore. We might need to target the shape of the cell. If we can stop the cell from building those "fingers" (BAMPs), we can stop the cancer from using its secret backdoor.
• Combination Therapy: The best way to kill these cancers might be to hit them with two punches: one drug to block the main highway (MAPK) and another to knock down the "VIP Lounge" (BAMPs). This would leave the cancer with nowhere to hide.

Summary

Think of the cancer cell as a criminal. For years, we thought the criminal's weird hat (the cell shape) was just a fashion choice. This paper proves the hat is actually a tool. It's a secret room where the criminal organizes the crime and hides from the police. If we take away the hat, the criminal loses their power, even if they still have the weapon.

Technical Summary

1. Problem Statement

For decades, it has been established that oncogenic RAS mutations (particularly KRAS) alter cell morphology by inducing membrane ruffles and lamellipodia via the activation of RAC1 and the ARP2/3 complex. However, the functional significance of these morphological changes remained unclear. The prevailing view was that these protrusions were merely passive outputs of RAS signaling. The central question addressed by this study is whether these branched actin-driven membrane protrusions (BAMPs) are active regulators that amplify oncogenic signaling, thereby contributing to the full "penetrance" (tumorigenic potential) of KRAS mutations. Specifically, the authors investigate if BAMPs create a unique microenvironment that enhances KRAS-effector interactions and drives proliferation independently of the canonical MAPK pathway.

2. Methodology

The study employed a multidisciplinary approach combining advanced live-cell imaging, optogenetics, biochemical assays, and in vivo models:

• Cell Models: The study utilized human pancreatic adenocarcinoma (SU.86.86, KRAS G12D), lung carcinoma (COR-L23, KRAS G12V), and patient-derived (MIA-PaCa2, KRAS G12C) cell lines. HPNE cells (normal pancreatic duct) were used for inducible BAMP formation experiments.
• Imaging Techniques:
  • Volumetric Light-Sheet Microscopy: Used to image dynamic BAMPs in 2D, 3D collagen matrices, spheroids, and cleared mouse xenografts with high spatiotemporal resolution.
  • Cleared-Tissue Light-Sheet Microscopy (ctASLM): Enabled visualization of BAMPs in intact subcutaneous mouse tumors.
  • Optogenetics: An iLID system was used to recruit the TIAM1 GEF domain to the membrane, inducing rapid, localized BAMP formation to test causality.
• Molecular Probes & Assays:
  • Split SNAP-Tag Reporter: Engineered to detect KRAS-effector interactions (KRASG12V + c-RAF1 RBD) via fluorescence recovery upon proximity.
  • Proximity Ligation Assay (PLA): Used to quantify endogenous KRAS-TIAM1 interactions in specific cellular compartments.
  • Western Blotting: Analyzed levels of Cyclin D1, phosphorylated ERK (MAPK pathway), and phosphorylated Merlin (tumor suppressor).
• Perturbations:
  • Chemical Inhibition: CK-666 (Arp2/3 inhibitor) and WGA (lectin blocking membrane protrusions) to disrupt BAMPs.
  • Genetic Manipulation: CRISPR-Cas9 for endogenous tagging of Merlin; doxycycline-inducible expression of myr-TIAM1DH/PH to force BAMP formation; expression of Merlin phosphomutants (S518A).
  • Pharmacological Inhibition: BI-2865 (pan-KRAS inhibitor) and Trametinib (MEK inhibitor).

3. Key Contributions & Results

A. BAMPs Enrich Oncogenic KRAS and Enhance Effector Interactions

• Localization: Oncogenic KRAS (G12D/G12V) was found to co-localize with F-actin and ARP3 in BAMPs across 2D, 3D, and in vivo xenograft models.
• Concentration: Optogenetic induction of BAMPs in MV3 cells resulted in a significant local enrichment of KRAS within the protrusions compared to non-protrusive regions.
• Interaction Amplification: Using the split SNAP-tag system, the authors demonstrated that KRAS-effector complex formation (KRAS-RBD) is significantly higher in BAMPs. Inhibiting BAMP formation with CK-666 disrupted these complexes and redistributed the signal.
• TIAM1 Feedback: Proximity ligation assays revealed that KRAS-TIAM1 interactions are significantly denser within lamellipodia/BAMPs. This suggests a positive feedback loop where BAMPs concentrate KRAS and its activator TIAM1, further driving RAC1 activation and BAMP growth.

B. BAMPs Drive Proliferation Independently of MAPK

• Proliferation Dependence: Disrupting BAMPs (via CK-666 or WGA) significantly reduced cell proliferation and Cyclin D1 expression in KRAS-mutant cells.
• MAPK Independence: Surprisingly, while BAMP inhibition reduced proliferation, it increased phosphorylated ERK (p-ERK) levels. Conversely, inhibiting MAPK (Trametinib) only partially reduced Cyclin D1 and proliferation.
• Additive Effect: Co-inhibition of BAMPs and MAPK led to a near-total abolition of Cyclin D1 and proliferation, indicating that BAMPs sustain a MAPK-independent proliferative pathway.

C. Mechanism: Inhibition of the Merlin Tumor Suppressor

• Merlin Sequestration: The study identified that BAMPs sequester the tumor suppressor Merlin (NF2) at the cell periphery.
• Phosphorylation: BAMP formation promotes the inhibitory phosphorylation of Merlin (at Serine 518) via the PAK1 kinase pathway.
• Cyclin D1 Regulation: When BAMPs are disrupted, Merlin becomes dephosphorylated (active), leading to the repression of Cyclin D1 and reduced proliferation.
• Validation: Overexpression of a non-phosphorylatable Merlin mutant (S518A) phenocopied the effect of BAMP inhibition, reducing Cyclin D1 levels even in the presence of oncogenic KRAS.

D. In Vivo Relevance

• Xenografts: In mouse subcutaneous tumors, BAMPs were observed primarily at the periphery of the tumor mass, correlating with zones of high cell proliferation.
• Consistency: The phenomenon was observed in both pancreatic and lung cancer models, suggesting it is a general mechanism for KRAS-driven tumorigenesis.

4. Significance

• Paradigm Shift: The paper challenges the view that cell morphology is merely a downstream effect of oncogenic signaling. Instead, it posits that morphology (BAMPs) is a critical regulator that configures the biochemical environment to amplify oncogenic signals.
• Therapeutic Implications:
  • Resistance Mechanism: The findings provide a mechanistic explanation for why MAPK inhibitors (like MEK inhibitors) often fail to fully suppress KRAS-driven tumors; the tumor relies on a parallel, BAMP-dependent, MAPK-independent pathway.
  • New Targets: Targeting the formation of BAMPs (e.g., Arp2/3 inhibition) or the Merlin-PAK1 axis could complement existing KRAS/MAPK inhibitors to overcome resistance.
• Biophysical Insight: The study highlights how physical constraints (narrow spaces in protrusions) can concentrate signaling molecules, increasing interaction probabilities and driving signal transduction efficiency.

Conclusion

The authors demonstrate that branched actin-driven membrane protrusions (BAMPs) are not passive byproducts but active "signaling hubs" that concentrate oncogenic KRAS and its effectors (specifically TIAM1). This spatial organization facilitates a positive feedback loop that inhibits the Merlin tumor suppressor, driving Cyclin D1 expression and cell proliferation via a pathway that bypasses the canonical MAPK cascade. This work reveals a critical, non-genetic mechanism of KRAS oncogenic penetrance and suggests new avenues for combination therapies in KRAS-mutant cancers.